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Randomized Phase III Trial of Piroxicam in Combination with
Mitoxantrone or Carboplatin for First-Line Treatment of Urogenital
Tract Transitional Cell Carcinoma in Dogs
S.D. Allstadt, C.O. Rodriguez Jr, B. Boostrom, R.B. Rebhun, and K.A. Skorupski
Background: Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with
either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration
of response.
Hypothesis/Objectives: To determine if the progression-free interval (PFI) of dogs with TCC treated with mitoxantrone
and piroxicam was different than that of dogs receiving carboplatin and piroxicam. The hypothesis was that the efficacy of
mitoxantrone is no different from carboplatin.
Animals: Fifty dogs with TCC without azotemia.
Methods: Prospective open-label phase III randomized study. Either mitoxantrone or carboplatin was administered every
3 weeks concurrently with piroxicam with restaging at 6-week intervals. Twenty-four dogs received carboplatin and 26
received mitoxantrone.
Results: Response was not different between groups (P = .56). None of the dogs showed complete response. In the mito-
xantrone group, there were 2 (8%) partial responses (PR) and 18 (69%) dogs with stable disease (SD). In the carboplatin
group, there were 3 PR (13%) and 13 (54%) dogs with SD. The PFI was not significantly different between groups (mitoxan-
trone = 106 days; carboplatin = 73.5 days; P = .62; hazard ratio 0.86; 95% confidence interval 0.47–1.56). Dogs with pros-
tatic involvement experienced a shorter survival (median, 109 days) compared to dogs with urethral, trigonal, or apically
located tumors; this difference was significant (median 300, 190, and 645 days, respectively; P = .005).
Conclusions and Clinical Importance: This study did not detect a different in outcome in dogs with TCC treated with
either mitoxantrone or carboplatin in combination with piroxicam.
Key words: Bladder cancer; Chemotherapy; cancer; canine; oncology; dog species.
Transitional cell carcinoma (TCC) is the most com-mon urinary tract cancer in the dog, developing
most often in the trigone region of the bladder and
commonly involves the urethra or prostate.1–5 Metasta-
sis to the regional lymph nodes, lungs, abdominal
organs, or bones is noted in approximately 1 of 6 cases
at the time of diagnosis, but is noted in up to 50% of
dogs at death.3,6–8 Because these characteristics often
limit the feasibility of surgical resection, chemotherapy
is commonly prescribed for canine TCC. However,
when possible, surgical excision should be considered,
since surgery has been shown to prolong survival times
in dogs with TCC.9,10 Local control is frequently chal-
lenging, and mortality most commonly occurs because
of urinary tract obstruction or clinical signs associated
with the primary tumor. The improved availability of
stenting has led to additional treatment options for
obstructive TCC.11,12
Piroxicam is a commonly used nonsteroidal anti-
inflammatory agent for managing TCC, with an 18%
reported overall response rate, a PFI of 4.3 months,
and an overall median survival time (MST) of
5.9 months.13 Piroxicam combined with mitoxantrone is
commonly used for managing TCC in dogs and has a
reported response rate of 35%, a median PFI of
194 days, and a MST of 291 days in dogs treated with
this combination.14 Responses to carboplatin and pirox-
icam have also been noted in dogs that have not
responded to other therapies, and the MST in these
dogs was 161 days.15 The overall response rate was
38% in that report; however, gastrointestinal toxicosis
was high (noted in 74% of dogs), and 25.8% was hospi-
talized.15 A PFI of 41 days has been reported in dogs
treated with carboplatin alone.16 While the PFI of mito-
xantrone combined with piroxicam has been published,
the PFI of carboplatin combined with piroxicam has
not. The PFI in dogs with TCC treated with cisplatin
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alone is 75–84 and is 124 days when combined with pir-
oxicam.17,18 Multiple other chemotherapeutic agents
have been described for the treatment of TCC in dogs
and response rates to cisplatin, doxorubicin, mitomycin
C, gemcitabine, vinblastine, and chlorambucil range
from 3 to 71% with PFI ranging from 75 to
329 days.10,16–23
Reported response of dogs with TCC to piroxicam
combined with either mitoxantrone or carboplatin is
similar, with overall response rates of 35% and 38%,
respectively.14,15 However, these combinations have not
yet been compared in a randomized prospective trial,
and it is currently not known whether either drug may
provide superior duration of response and thus be indi-
cated as first-line treatment. The purpose of this open-
label, randomized phase III study was to determine if
the response rate and PFI of dogs with chemotherapy-
na€ıve urinary tract TCC treated with mitoxantrone and
piroxicam was different than that of dogs receiving car-
boplatin and piroxicam.
Materials and Methods
This open-label, randomized trial compared piroxicam com-
bined with either mitoxantrone or carboplatin in dogs with cyto-
logically or histopathologically confirmed TCC of the urinary
tract. Dogs were prospectively enrolled, treated, and followed up
at the University of California-Davis Veterinary Medical Teaching
Hospital (UCD VMTH) between December 2006 and March
2013. For enrollment, dogs had a cytologic or histopathologic
diagnosis, an abdominal ultrasound, 3-view thoracic radiographs,
a complete blood count, serum biochemistry panel, urinalysis, and
informed owner consent. Dogs with confirmed locoregional lymph
node metastasis were accepted; however, dogs that had metastasis
to other organs such as the spleen, liver, or lungs were excluded
(because of short life expectancy limiting evaluation of response).
Urine cultures were routinely performed at diagnosis and regularly
throughout treatment, particularly if signs changed.
A simple randomization technique with a sealed shuffled enve-
lope system was used to randomize dogs to receive either mitoxan-
trone or carboplatin chemotherapy. All dogs were prescribed
piroxicam at a target dose of 0.3 mg/kg PO once daily. Mitoxan-
trone was started at a dose of 5.5 mg/m2 in dogs >15 kg or 5 mg/
m2 in dogs ≤15 kg; carboplatin was started at a dose of 300 mg/
m2 in dogs >15 kg or 10 mg/kg in dogs ≤15 kg. Both drugs were
prescribed IV at 21-day intervals. The primary endpoint of this
study was progression-free interval (PFI). Median doses reported
were calculated on the second dose to account for dose reductions
because of adverse events.
All dogs had a baseline abdominal ultrasound and 3-view tho-
racic radiographs, which were repeated every 6 weeks to monitor
disease and performed at the UCD VMTH. Response was assessed
according to response evaluation criteria in solid tumors
(RECIST) guidelines.24–27 In dogs with lymph node metastasis,
lymph nodes were included in the response assessment.
Data collected for each dog included signalment, weight, tumor
location and size, cytology or histopathology results or both, stag-
ing results, treatment group, RECIST response, clinical improve-
ment (based on owner questionnaires), toxicities, dose reductions,
treatment delays, outcome, rescue treatment, cause of death, and
necropsy information, if available. Owners completed a question-
naire at each visit describing the dog’s clinical signs at home since
the previous visit. Adverse events were graded using the Veterinary
Cooperative Oncology Group common terminology criteria for
adverse events, version 1.0.28 Complete blood counts were per-
formed 7 days after mitoxantrone administration, 7–14 days after
carboplatin administration, and repeated before the next treatment
for both drugs to monitor for hematologic toxicity. A minimum of
6 chemotherapy treatments were administered as long as the dis-
ease was responsive or stable.
Rescue treatment was allowed, and crossover treatment with
the alternative drug was encouraged although not required when
progressive disease (PD) was documented. The primary endpoint
was PFI, which was defined as the time between first chemother-
apy treatment and ultrasonographically documented PD. If pro-
gression was not documented before death and cause of death was
not known, progression was assumed at the date of death. Sur-
vival was defined as time from the start of treatment to death. Sur-
vival was censored for dogs that were currently being treated
without evidence of progression.
A power analysis was performed to estimate the number of
dogs needed to detect a statistically significant difference in PFI
between the 2 treatment groups. Based on the literature, expecta-
tions were that dogs with TCC treated with platinum chemother-
apy would experience an approximate PFI of around 80 days (ie,
the average of the 4 reported PFIs in platinum-treated cases).16–18
Using an alpha level of 0.05 and a power of 0.80, a minimum of
41 dogs were needed for enrollment over a 6-year time period to
detect a significant difference in a PFI of 80 days for carboplatin-
treated dogs and 194 days for mitoxantrone-treated dogs. The
t-test was used to compare continuous variables between treatment
groups. Depending on the number of dogs in each category, the
Fisher’s exact test or v2 test was used to compare categorical vari-
ables between treatment groups. Factors compared between
groups included age, sex, weight, tumor location, stage, and first-
line treatment drug. The Kaplan-Meier method was used to esti-
mate PFI and MST, and the log-rank test was used to compare
PFI and MST times between groups. Statistical analyses were
performed by commercial software,a and P < .05 was considered
significant.
Results
Fifty dogs with measurable gross disease were
enrolled between September 2006 and March 2013. All
dogs received piroxicam; 24 received carboplatin and 26
received mitoxantrone. There were 13 mixed-breed
dogs; 5 Labrador retrievers; 3 Scottish Terriers; 2 each
of the Australian shepherd, beagle, dachshund, Pit Bull
Terrier, and West Highland White Terrier; and 24 other
breeds of dogs. There were 28 (56%) spayed females, 1
(2%) intact female, and 21 (42%) castrated males. The
mean weight of all dogs was 24.4 kg (range 4.2–
69.0 kg). Thirty-two dogs were diagnosed via cytology
via fine needle aspiration of a urinary bladder or pros-
tatic mass, 16 via histopathology, and 2 with both
cytology and histopathology. Characteristics of the 2
groups are summarized in Table 1 and were not statisti-
cally different.
After 6 weeks of first-line treatment, no complete
responses were noted. Partial responses (PR) were noted
in 2 (8%) and 3 (13%) dogs in the mitoxantrone and
carboplatin groups, respectively. Stable disease (SD)
was noted in 18 (69%) and 13 (54%) dogs in the mito-
xantrone and carboplatin groups, respectively. There
was no difference in the objective response rates for
either drug (P = .28). The PFI was not significantly
different between groups and was 106 days (range
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21–383 days) for the mitoxantrone-treated group and
73.5 days (range 13–548 days) for the carboplatin-trea-
ted group (P = .62; hazard ratio 0.86; 95% CI 0.47–
1.56; Fig 1).
Twenty dogs in each group could be evaluated for
subjective response based on the presence of clinical
signs before treatment. In 10 dogs, clinical response was
not evaluated because of the lack of signs (n = 4), surgi-
cal resection of the tumor (n = 2), placement of a stent
(n = 1), euthanasia (n = 1), or lost to follow-up (n = 2).
In the mitoxantrone group, 18/20 (90%) dogs had
improvement in signs, and 2/20 (10%) had no change
in signs. In the carboplatin group, 13/20 (65%) had
improvement in clinical signs, and 7/20 (35%) had sta-
ble clinical signs. These differences were not statistically
significant (P = .13).
The mean number of treatments was 4.7 (range 1–13)
in the mitoxantrone group and 4.5 in the carboplatin
group (range 1–19). Twelve carboplatin-treated dogs
crossed over to be treated with mitoxantrone. In this
group, response rates included 1 (8%) PR, 7 (58%) SD,
and 5 (42%) PD. These dogs were treated with a mean
of 4.5 doses of carboplatin (range: 1–19) and a mean of
4.7 doses (range: 1–9) of mitoxantrone. Twelve mito-
xantrone-treated dogs crossed over to be treated with
carboplatin. In this group, response rates included no
PR, 2 (17%) SD, and 9 (75%) PD. These dogs were
treated with a mean of 5.4 doses (range: 2–13) of mito-
xantrone and a mean of 3.7 doses (range 2–12) of car-
boplatin. When comparing all dogs, there was no
difference in PFI between female and male dogs
(P = .30). Overall, dogs with lymph node metastasis at
the time of treatment experienced a significantly shorter
PFI (47 days) compared to dogs without evidence of
metastasis (107 days, P = .0004; hazard ratio 0.11; 95%
CI 0.03–0.37). In all but 5 dogs, the cause of failure
was progression of the local tumor. Two dogs were lost
to follow-up, and thus cause of failure was uncertain.
Two dogs (one in each group) with prostatic tumors
developed pulmonary metastatic disease by their 6-week
recheck. One dog with a trigonal bladder mass devel-
oped local lymph node progression on carboplatin.
As rescue treatment was allowed, overall MST was
not a primary endpoint but was 247.5 days when mito-
xantrone was the first-line treatment and 263 days when
carboplatin was the first-line treatment (P = .47; hazard
ratio 1.25; 95% CI 0.69–2.27; Fig 2). Twenty-four cases
did not receive any rescue treatment after progression
on the first drug. Twenty-six dogs received rescue treat-
ment; 15 received only 1 rescue treatment (2 total
drugs), 7 received 2 rescue therapies (3 total drugs), 3
received 3 rescue therapies (4 total drugs), and 1 dog
received 4 rescue therapies (5 total drugs). Dogs that
received 3 or more chemotherapy agents experienced a
MST of 402 days compared to a MST of 190 days in
dogs who received 1–2 chemotherapy agents (P = .002).
Dogs with prostatic involvement (n = 14) had signifi-
cantly shorter survival (109 days) compared to dogs
with urethral, trigonal, or apically located tumors (300,
190, and 645 days, respectively; P = .005; Fig 3). Ure-
thral involvement was not a significant factor in sur-
vival compared to all other locations (300 days versus
105 days, respectively, P = .08).
Fourteen dogs started mitoxantrone as a first-line
treatment at 5 mg/m2 (≤15 kg). Four of these dogs had
dose reductions because of neutropenia, and 7 had dose
escalations because of no toxicities observed at 5 mg/
m2. Two dogs that started mitoxantrone at 5.5 mg/m2
required dose reductions because of neutropenia, and 1
dog had a dose reduction because of a grade 1 diarrhea
at the owner’s request. Overall, in the mitoxantrone
group, when treated as a first-line treatment, 7/26 dogs
(27%) had dose reductions because of adverse events.
The median first-line mitoxantrone dose of all dogs cal-
culated on the second dose was 5.13 mg/m2 (range 4–
5.5 mg/m2). Eight dogs started carboplatin as a first-line
treatment at 10 mg/kg (≤15 kg), and 2 of these dogs
had dose reductions because of neutropenia. Sixteen
dogs started carboplatin as a first-line treatment at
300 mg/m2 and only 1 had a dose reduction because of
owner preference after a grade 1 neutropenia was noted.
Overall, in the carboplatin group, when treated as a
first-line treatment, 3/24 (13%) dogs had their doses
Table 1. Comparison of dog and tumor characteristics
between first-line treatment groups.
Characteristic Mitoxantrone Carboplatin P Value
Mean age (years) 10.11 10.6 .45
Sex
Female 14 15 .58
Male 12 9
Mean weight (kg) 25.86 22.73 .42
Tumor location









Fig 1. Kaplan-Meier curves plotting progression-free interval in
dogs with transitional cell carcinoma treated with piroxicam and
mitoxantrone (solid line) and piroxicam and carboplatin (dotted
line; P = .62).
Canine TCC Phase III Trial 263
reduced because of adverse effects. In dogs weighing
>15 kg, the median calculated second dose of carbopla-
tin was 297.19 mg/m2 (range, 255–300 mg/m2), and in
dogs weighing <15 kg, the median second dose of car-
boplatin was 9.66 mg/kg (range, 8.3–10 mg/kg).
Combining first-line and crossover treatments, a total
of 38 dogs received mitoxantrone and 35 dogs received
carboplatin, and adverse events are reported for all
dogs that received the drugs as either a first-line or as
rescue treatment. Overall, more dogs treated with car-
boplatin experienced some form of gastrointestinal toxi-
cosis (9/35; 26%) than did dogs treated with
mitoxantrone (3/38; 8%); however, this difference did
not reach statistical significance (P = .06). In contrast,
myelosuppression, specifically neutropenia, was statisti-
cally (P = .02) more common after mitoxantrone (15/
38; 40%) than after carboplatin (5/35; 14%).
Table 2 summarizes adverse effects. Twelve dogs had
dose reductions because of adverse events: 4/35 (11%)
dogs that received carboplatin and 8/38 (21%) dogs
that received mitoxantrone. Ten of these reductions
were because of neutropenia and 2 were because of
concurrent neutropenia and gastrointestinal abnormali-
ties.
Neutropenia was more likely in the mitoxantrone-
treated group, and thrombocytopenia was noted only
in the carboplatin-treated group (Table 2). Six of 35
(17%) dogs in the carboplatin-treated group received
treatments every 28 days because of a 21-day carbopla-
tin nadir. Two dogs from each group had simultaneous
neutropenia and gastrointestinal upset. Three dogs
(6%) were hospitalized because of adverse effects, 1
after mitoxantrone administration (5 mg/m2) because
of grade 4 neutropenia with concurrent fever and 2
after carboplatin administration (each at 10 mg/kg),
with 1 dog presenting with neutropenia, decreased
appetite, and abdominal discomfort, and the other pre-
senting with vomiting that began 24 hours after treat-
ment. Chemotherapy was discontinued in 1 dog (2%)
because of grade 2 vomiting after mitoxantrone (dose:
5.5 mg/m2). Most high-grade adverse effects were
because of neutropenia, and most dogs recovered with-
out intervention other than prophylactic antibiotic
administration.
Piroxicam was discontinued because of adverse events
in 16 (32%) dogs: 9 dogs in the carboplatin group and
7 dogs in the mitoxantrone group. Discontinuation was
because of the development of azotemia in 6/16 (38%)
dogs (3 from each group). In 2 dogs from each group,
concurrent progression of disease was noted, so the
development of azotemia may have been related to
either piroxicam or to disease progression. In 2 addi-
tional dogs (1 from each group), the development of
azotemia occurred without documentation of progres-
sive disease. Piroxicam was discontinued in 11/16 dogs
(69%) because of adverse gastrointestinal clinical signs
that appeared to be unrelated to chemotherapy adminis-
tration. In 1 dog, discontinuation occurred because of
both azotemia and concurrent gastrointestinal clinical
signs.
Fig 2. Kaplan-Meier curves plotting median survival time in dogs
with transitional cell carcinoma treated with piroxicam and mito-
xantrone (solid line) and piroxicam and carboplatin (dotted line;
P = .47).
Fig 3. Kaplan-Meier curves plotting median survival time in dogs
without prostate involvement (solid line) and with prostate
involvement (dotted line; P = .005).
Table 2. Summary of toxicosis in all mitoxantrone




Grade 1 1 2
Grade 2 3 0
Grade 3 4 2
Grade 4 4 1
Thrombocytopenia
Grade 1 0 1
Grade 2 0 1
Grade 3 0 0
Grade 4 0 1
Vomiting
Grade 1 0 7
Grade 2 1 1
Diarrhea
Grade 1 2 0
Grade 2 1 2
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Discussion
The purpose of this open-label, randomized phase III
study was to determine if PFI of treatment-na€ıve dogs
with TCC patients receiving mitoxantrone and piroxi-
cam was different than those receiving carboplatin and
piroxicam. We did not identify a statistically significant
difference in the PFI of dogs between these 2 groups;
however, a false negative result because of a type II
error cannot be ruled out. A power analysis was per-
formed before enrollment to minimize this possibility,
but the analysis was based on the limited data available
on PFI in TCC dogs receiving carboplatin. Thus, as
with any power analysis, it is possible that some of the
assumptions made when performing the analysis could
have been erroneous, and detecting a smaller difference
between groups may require more dogs than were
planned for in this study.
The results of this study might have also been
affected by differences in stage of disease between the 2
groups. Seven dogs in the carboplatin group had metas-
tasis at the start of treatment versus only 2 dogs in the
mitoxantrone group. In addition, differences in tumor
burden and location, including ureteral involvement,
may have influenced outcome. One dog from each
group had surgical debulking of its tumor (but had
gross tumor remaining at enrollment) that may have
affected its outcome.
Dogs with prostatic involvement did experience a
shorter PFI in this study, supporting previously pub-
lished data describing prostatic involvement as a nega-
tive prognostic factor in canine TCC.3 Dogs with lymph
node metastasis experienced a significantly shorter sur-
vival time (47 days) than dogs without lymph node
metastasis (P = .0004).
Another finding of note in this study is the statisti-
cally significant difference in survival between dogs
receiving multiple rescue agents. Dogs who received 3
or more chemotherapy agents experienced an MST of
402 days compared to 190 days for dogs that received 1
or 2 chemotherapy agents (P = .002). These longer sur-
vival times may be influenced by more dedicated/afflu-
ent owners, or perhaps these dogs had tumors that
progressed more slowly, allowing time to incorporate
additional treatment.
Clinically, most dogs experienced an improvement of
their urinary tract clinical signs based on questionnaire
assessment: 90% of dogs in the mitoxantrone group
and 75% of dogs in the carboplatin group. While these
responses could be attributable, in part, to the piroxi-
cam or to antibiotic treatment in those that had urinary
tract infections, they are evidence to support treatment
in dogs with TCC as the results support the likelihood
that treatment will improve dogs’ quality of life. Urine
cultures were performed at diagnosis and routinely
throughout treatment, especially when signs changed.
The response rates and PFI reported herein differ
somewhat from those previously reported. Specifically,
1 study reported a 35% overall response rate in dogs
receiving mitoxantrone and piroxicam compared to 8%
seen in this study, and another study reported a 38%
response rate in dogs receiving carboplatin and piroxi-
cam compared to 13% seen in this study.14,15 The rea-
son for this difference is not immediately clear, and
direct comparison of 2 studies performed at different
institutions at different times is not possible. It is likely
that the difference between ultrasonographic measuring
techniques between these studies played a role. Both
previous studies used a method of uniform bladder dis-
tension through catheterization, fluid removal, and dis-
tension that was not used in this study. The authors
opted not to pursue this technique in this study in light
of the added expense and risk of repeated anesthesia
and bladder catheterization every 6 weeks, as well as
the evidence that measurement variability is significant
even with uniform bladder distension techniques.29 In
addition, the authors chose to more closely mirror
response results as they would be in routine practice.
Assessment of response using abdominal ultrasonog-
raphy is a limitation that may have yielded inconsistent
response data. Recently, 2-D ultrasonography has been
determined to be an inconsistent method of determining
bladder tumor size, and computed tomography has
been described as the most accurate method.29–31 How-
ever, there were no complete responses and few PR in
this study—only 5 dogs in the study had a PR based on
ultrasound measurement of the longest diameter. All
other dogs experienced either SD or PD. Given this
information, it is unlikely that response was overreport-
ed, although it may have been underreported. Com-
puted tomography (CT) imaging of the bladder has
become the standard of care for monitoring bladder
tumors in humans. Perhaps, veterinary oncologists
should consider this modality in their patients; however,
1 limitation of this modality may be cost, as CT often
requires general anesthesia, and the cost is significantly
higher than other available imaging modalities. Cer-
tainly, further research into optimal tumor measuring
methods is needed.
The PFI of dogs in this study treated with first-line
mitoxantrone and piroxicam (109 days) was shorter than
the 194 days previously reported in the literature; how-
ever, the tumor imaging schedules in these 2 studies dif-
fered.14 In earlier studies, initial response to treatment
was documented 42 days after starting treatment and
then again at 3 months after completing chemotherapy,
whereas this study involved repeat ultrasounds every
6 weeks.14 Likely, more frequent ultrasounds allowed
earlier detection of PD in this study, resulting in a shorter
reported PFI. This theory is supported by similar
reported survival times by prior studies, and this study
when comparing data using similar censoring methods
(291 days versus 247.5 days). Another difference between
this and previous studies is in response criteria used. Pre-
vious studies have used the World Health Organization
(WHO) response criteria, whereas the study reported
herein used RECIST criteria. While these 2 criteria
groups correlate well, it is possible that responses may
have been classified differently using the WHO system,
affecting the ability to directly compare results.
One limitation of this study is the lack of a piroxi-
cam-alone arm. It is possible that some responses might
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have been attributable to piroxicam alone; however,
given the longer survival times noted in these cases
compared to historical survival times in dogs treated
with piroxicam alone, it is likely that chemotherapy
extends survival times in dogs with TCC. The reported
MST in dogs treated with piroxicam alone is
5.9 months, which is numerically inferior to the MST of
8–11.4 months reported with carboplatin and mitoxan-
trone chemotherapy in combination with piroxicam.
This implies that the addition of chemotherapy is of
some benefit. Nonetheless, a randomized prospective
trial comparing single agent piroxicam to piroxicam in
combination with chemotherapy should be performed
to truly identify if there is a benefit to administering
chemotherapy in dogs with TCC.
Perhaps controversially in this study, 32 dogs were
diagnosed by transabdominal cytology via fine-needle
aspiration of a urinary bladder or prostatic mass, which
may raise concern for the risk of tumor seeding. Nec-
ropsy of 10 of these 32 dogs showed no evidence of
transabdominal or peritoneal seeding of the tumor.
Cytology is inexpensive and efficient compared to cys-
toscopy or traumatic catheterization, both of which
require anesthesia; however, transabdominal cytologic
diagnosis is discouraged in dogs with a long life expec-
tancy, such as those with surgically resectable or small
tumors.
Neutropenia was noted in 40% of the mitoxantrone-
treated dogs, indicating that close monitoring of hema-
tologic parameters is indicated. Gastrointestinal toxico-
sis (most notably, vomiting) was more frequently
noted in the carboplatin-treated group, although it was
most often mild and self-limiting. Overall, both thera-
pies were well tolerated, and only 3 patients (6% over-
all) were hospitalized or discontinued treatment
because of severe adverse effects. Most patients that
experienced high-grade neutropenia were asymptomatic
and recovered without intervention other than prophy-
lactic antibiotics. Gastrointestinal toxicosis was far less
common in the carboplatin-treated dogs (26%) in this
study compared to a previous study where 74% of
dogs with TCC receiving the combination of carbopla-
tin and piroxicam developed gastrointestinal toxico-
sis.15 Similarly, the hospitalization rate in this study
was much lower than previously reported. The reason
for this difference is unclear; however, current results
suggest that this drug combination might not be as
toxic as previously reported and should be considered
in dogs with TCC. One additional weakness of the
study might be that 17% of the carboplatin-treated
dogs received carboplatin every 4 weeks instead of
every 3 weeks because of a 21-day nadir, delaying their
treatment schedule, which reduces the dose intensity of
carboplatin. This might have influenced response to
carboplatin.
One third of the dogs in this study had piroxicam
discontinued because of adverse effects. The majority
(68.8%) were discontinued because of gastrointestinal
signs that appeared to be unrelated to chemotherapy,
based on treatment of signs and reinitiation of
piroxicam with recurrence of signs. One third was
discontinued because of azotemia, which was because
of either direct nephrotoxicity or tumor progression.
These adverse effects demonstrate the need for moni-
toring for toxicosis. Other nonsteroidal anti-inflamma-
tory drugs have been described for the management of
TCC and might be considered as alternatives in dogs
that do not tolerate piroxicam.32,33
In conclusion, we did not detect a difference in PFS
between the 2 groups studied herein. Both combinations
were tolerated in the majority of dogs, although some
dogs experienced toxicosis that required dose reductions
or treatment, emphasizing the need for monitoring. The
data presented herein make up the first phase III clini-
cal trial comparing therapies for TCC in the dog.
Future investigations into the efficacy of other pub-
lished therapies as a first-line treatment for canine TCC
should also be performed.
Footnotes
a Prism version 5.0c, GraphPad, La Jolla, CA
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